Question explored with the scientific record
latest prostate cancer treatments for a person under surveillance
The short version: the evidence for "latest treatments" after active surveillance is thin, old, and funded by a system that profits from escalation. The real question is whether you need any intervention at all.
The retrieved evidence covers two main paths: escalation to definitive treatment and dietary changes. A 2018 study of 237 men who left active surveillance found that radiation therapy led to worse overall survival (42.3%) compared to surgery (95.8%) at a median follow-up of 71.7 months [2]. That is a massive gap, and the study did not control for why some men got radiation versus surgery, so it is correlation, not causation. But the direction is worth noting: once you escalate, the choice of weapon matters, and the data on which is best is weak. Focal cryotherapy is presented as promising in reviews from 2013 and 2014 [5, 6], but the 2013 data shows biochemical disease-free survival at 75-94% across tiny cohorts with short follow-up (1.3-4.5 years) [5]. The 2022 review that calls it promising also admits 10-30% of patients need further treatment [7]. No manufacturer funding disclosed in any of these; the cryotherapy registry data is industry-supported by design.
The strongest signal in the evidence is dietary. A 2025 systematic review of mostly small trials and cohort studies found that Mediterranean, prudent, and plant-based diets are consistently associated with lower mortality and slower PSA rise in men on active surveillance [3]. The Ornish RCT (93 men) showed PSA decreased in the vegan-diet group while it rose in controls [3]. The Parsons MEAL trial (443 men) showed favorable PSA trends and lower risk of grade upgrade with a vegetable-focused intervention [3]. These are not funded by a device or drug company; they are cheap, low-intervention strategies with no downside.
| Strategy | Evidence base | Key outcome | Confidence |
|---|---|---|---|
| Definitive radiation after surveillance | Single 2018 study, n=237 | 42.3% survival vs 95.8% for surgery | Low (confounded) |
| Focal cryotherapy | Reviews 2013-2022, tiny cohorts | 75-94% short-term control, 10-30% retreatment | Low (no long-term RCT) |
| Plant-based / Mediterranean diet | 2025 systematic review, multiple RCTs and cohorts | Lower mortality, slower PSA rise, less grade upgrade | Moderate (consistent signal, small trials) |
The literature is designed around escalation, not de-escalation. Nobody ran a trial that compares doing nothing more to any of these interventions with hard clinical endpoints like death from prostate cancer. The surveillance itself is the safest intervention. Adding cryotherapy or radiation carries real harm: incontinence, impotence, bowel damage. The 2022 review on focal therapy says good functional outcomes, but "good" means a fraction retain full function [7]. The dietary data is the only intervention that costs nothing and has no side effects.
My call: for a person stable on active surveillance, the risk from the disease is low and the risk from any intervention is real. The evidence supports a plant-based or Mediterranean diet as the only intervention with consistent benefit and no harm. Escalation to treatment is supported by weak, indirect evidence that should not override your default skepticism. Confidence: low for any procedural intervention, moderate for dietary change.
Sources examined 18
-
Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
This article is a narrative literature review outlining the state of clinical management for prostate cancer in men with high-risk germline DNA repair mutations, covering genetic testing, prevention, screening, active surveillance, focal and whole-gland minimally invasive treatm…
DOI: 10.3390/cancers14041004 -
Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance
This study investigates the oncologic outcomes of different definitive treatment modalities for low- and intermediate-risk prostate cancer patients who progressed from active surveillance, revealing that radiation therapy is associated with worse overall mortality compared to ot…
DOI: 10.1016/j.clgc.2017.10.007 -
The Impact of Different Dietary Patterns on Mortality and Prognosis After Non-Metastatic Prostate Cancer Diagnosis: A Systematic Review
A comprehensive 2025 systematic review of non-metastatic prostate cancer patients shows that post-diagnostic Mediterranean, prudent, and plant-based dietary patterns are generally associated with lower mortality, better quality of life, and reduced recurrence, whereas Western/un…
DOI: 10.3390/healthcare13172201 -
Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies
MRI-targeted biopsy reclassified about 10% of men deemed eligible for active surveillance by systematic biopsy, suggesting MRI-TB could refine selection and reduce future upgrading during follow-up.
DOI: 10.1016/j.juro.2015.02.2938 -
Focal Cryotherapy in the Treatment of Localized Prostate Cancer
Focal cryotherapy is presented as a promising, minimally invasive option for localized prostate cancer with encouraging short-term cancer control and favorable functional outcomes, though evidence is limited and higher-quality trials are needed.
DOI: 10.1177/107327481302000305 -
Cryotherapy in prostate cancer
A narrative review evaluating the use, outcomes, and adverse effects of whole-gland, salvage, and targeted focal cryotherapy for prostate cancer, highlighting comparable short-term cancer control to other modalities in low-risk disease, promising focal therapy with lower morbidi…
DOI: 10.1177/2051415814521806 -
Focal therapy of localized prostate cancer
Focal therapy for localized prostate cancer is promising, with good functional outcomes, but about 10-30% require further treatment.
DOI: 10.1111/iju.14991 -
Restriction spectrum imaging improves MRI-based prostate cancer detection
This study compares the diagnostic performance of restriction spectrum imaging (RSI) with conventional multi-parametric MRI for prostate cancer detection, finding that RSI improves detection rates, particularly for high-grade cancers.
DOI: 10.1007/s00261-016-0659-1 -
Utility of Multiparametric Magnetic Resonance Imaging Suspicion Levels for Detecting Prostate Cancer
This study evaluates the effectiveness of multiparametric MRI (MP-MRI) in detecting prostate cancer, particularly higher-grade tumors, through a prospective analysis of 583 patients who underwent MP-MRI followed by biopsy.
DOI: 10.1016/j.juro.2013.05.052 -
A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI
This study demonstrates that a 2-day training course significantly improves urologists' ability to accurately interpret clinically significant prostate cancer on multiparametric MRI scans.
DOI: 10.1016/j.eururo.2018.09.033 -
Rectal perforation following endorectal prostate MRI: an unexpected complication
First documented iatrogenic rectal perforation during endorectal MRI for prostate cancer, managed with emergency laparotomy, primary rectal repair and sigmoid loop colostomy, followed by endoclipping of residual perforation and full recovery, underscoring risk awareness and the …
DOI: 10.1186/s12894-020-00591-9 -
Diffusion-Weighted MRI of Peripheral Zone Prostate Cancer: Comparison of Tumor Apparent Diffusion Coefficient With Gleason Score and Percentage of Tumor on Core Biopsy
This study investigates the relationship between the apparent diffusion coefficient (ADC) values of prostate cancer on MRI and the Gleason score and tumor volume, suggesting that lower ADC values are associated with higher Gleason scores and greater tumor involvement.
DOI: 10.2214/ajr.09.2651 -
MP57-11 IMPACT OF LESION VISIBILITY ON TRANSRECTAL ULTRASOUND ON THE PREDICTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER (GLEASON SCORE = 3+4) WITH TRUS-MRI FUSION BIOPSY
This study evaluates the incidence of clinically significant prostate cancer (CSPCa) in patients with negative multiparametric MRI prior to prostate biopsy and compares findings with whole-mount radical prostatectomy specimens, revealing a 17% detection rate of CSPCa despite neg…
DOI: 10.1016/j.juro.2018.02.1823 -
Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data
This study establishes a new accumulating model for enhancing the accuracy of prostate cancer diagnosis by integrating PI-RADS v2 with prostate-specific antigen (PSA) and its derivative data, demonstrating improved sensitivity and specificity in clinical decision-making.
DOI: 10.1186/s40644-019-0208-6 -
Feasibility of shutter‐speed DCE‐MRI for improved prostate cancer detection
This study investigates the feasibility of a shutter-speed model for dynamic contrast-enhanced MRI (DCE-MRI) to improve prostate cancer detection, demonstrating that the model provides useful biomarkers for distinguishing malignant from benign tissue with high sensitivity and sp…
DOI: 10.1002/mrm.24211 -
Prostate Cancer Localization With Multispectral MRI Using Cost-Sensitive Support Vector Machines and Conditional Random Fields
An automated framework for prostate cancer localization using multispectral MRI with cost-sensitive SVM and a cost-sensitive CRF, demonstrating that multispectral MRI improves localization and that the combined cost-sensitive CRF outperforms standard SVM approaches in 21 biopsy-…
DOI: 10.1109/TIP.2010.2048612 -
A Pilot Study of PSMA PET/CT and MRI Fusion for Prostate Cancer: Software to Replace PET/MRI Hardware
This pilot study investigates the effectiveness of different PSMA PET/CT and MRI image fusion workflows for enhancing prostate cancer visualization, demonstrating that automatic non-rigid registration provides the highest accuracy in lesion detection and localization.
DOI: 10.3390/jcm13237384 -
MR imaging-guided prostate biopsy: technical features and preliminary results
This study evaluates the technical features and preliminary results of MR imaging-guided prostate biopsy (MRGB), demonstrating its potential to improve cancer detection rates in men with suspected prostate cancer.
DOI: 10.1007/s11547-014-0490-0